Heart Failure With Reduced Ejection Fraction study: Metoprolol Succinate vs Carvedilol
Official title Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
ClinicalTrials.gov ID: NCT06964464
What this study is testing
What is Metoprolol Succinate?
Metoprolol Succinate is an investigational medicine, being studied as a potential treatment for heart failure with reduced ejection fraction (hfref).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see which drug better prevents ICD shocks, heart‑related hospital stays, or death, and how they affect quality of life.
- Who it's for
- Adults with reduced‑ejection‑fraction heart failure who already have an ICD and are taking metoprolol succinate.
- What's involved
- Participants are randomly kept on metoprolol or switched to carvedilol, then have regular check‑ups, ICD interrogations, medication checks, and complete quality‑of‑life surveys.
- Time commitment
- Up to 3 years of follow‑up with periodic clinic visits and device checks.
- Phase 4: studies an already-approved treatment
- Time commitment: about 3 years
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability
- Current treatment with metoprolol succinate and willing to switch to carvedilol
- LVEF \<50% during the past 12 months prior to consent
You likely can't join if
- Unwilling or unable to follow the protocol
- Treatment with any other ßB than metoprolol succinate or no ßB treatment
- Known prior intolerance or contraindication to carvedilol
- Systolic blood pressure \<100 mmHg
- Enrollment in another clinical trial
- Inability or unwilling to consent
The study team makes the final eligibility decision.
Where it is enrolling
- Scottsdale, Arizona, United States
- Rome, Georgia, United States
- Shawnee Mission, Kansas, United States
- Detroit, Michigan, United States
- Columbia, Missouri, United States
- Omaha, Nebraska, United States
- Brooklyn, New York, United States
- Rochester, New York, United States
- Tyler, Texas, United States
- Salt Lake City, Utah, United States
- Richmond, Virginia, United States
- Madison, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 3 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Scottsdale, Arizona, United States; Rome, Georgia, United States; Shawnee Mission, Kansas, United States; Detroit, Michigan, United States; Columbia, Missouri, United States; Omaha, Nebraska, United States and 6 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.